All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Approves Vorasidenib for IDH1/2+ Grade 2 Astrocytoma or Oligodendroglioma

August 6th 2024

The FDA has approved vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.

FDA Clears Companion Diagnostic for Afami-Cel in Pretreated Metastatic Synovial Sarcoma

August 6th 2024

The FDA cleared the SeCore CDx HLA A Sequencing System as a companion diagnostic for afamitresgene autoleucel in advanced synovial sarcoma.

IMRT Alone is Non-Inferior to CCRT in Nasopharyngeal Carcinoma

August 6th 2024

Radiotherapy was non-inferior vs chemoradiotherapy in patients with nasopharyngeal carcinoma, and less toxicity was observed with radiotherapy alone.

EO-3021 Generates Responses in Advanced Solid Tumors Likely to Express CLDN18.2

August 6th 2024

EO-3021 was safe and led to responses in advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2.

Pirtobrutinib Produces Responses in BTK Inhibitor–Naive R/R CLL/SLL

August 6th 2024

Pirtobrutinib generated responses in BTK inhibitor–naive relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

EMA Grants Orphan Drug Designation to SLS009 for R/R PTCL

August 6th 2024

The European Medicines Agency has granted orphan drug designation to SLS009 for relapsed/refractory peripheral T-cell lymphoma

FDA Accepts sNDA for Cabozantinib in Advanced Pancreatic and Extra-Pancreatic NETs

August 6th 2024

The FDA has accepted a supplemental new drug application for cabozantinib in advanced pancreatic and extra-pancreatic neuroendocrine tumors.

Emerging HER2+ Breast Cancer Research Uses Innovative Combinations of Standard Agents

August 6th 2024

Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.

Residual Cancer Burden May Prognosticate Outcomes With Neoadjuvant Therapy in Prostate Cancer

August 6th 2024

Praful Ravi, MB, BChir, MRCP, discusses an analysis measuring residual cancer burden in localized prostate cancer after neoadjuvant therapy and surgery.

UV1 Plus Pembrolizumab Fails to Yield Survival Benefit in Metastatic/Recurrent Head and Neck Cancer

August 5th 2024

UV1 plus pembrolizumab did not improve progression-free survival or overall survival in patients with metastatic or recurrent head and neck cancer.

Outpatient Treatment With Subcutaneous Epcoritamab Shows Feasibility in R/R DLBCL and Follicular Lymphoma

August 5th 2024

Subcutaneous epcoritamab demonstrated safety when given in the outpatient setting in relapsed/refractory diffuse large B-cell and follicular lymphoma.

Epcoritamab Optimization Lowers Neurotoxicity, Boosts Outpatient Feasibility in Follicular Lymphoma

August 5th 2024

Julie M. Vose, MD, MBA, discusses results with epcoritamab from the follicular lymphoma cycle 1 optimization cohort of the phase 1/2 EPCORE NHL-1 trial.

Chemotherapy-Free Approaches Are at the Forefront in MCL

August 5th 2024

Alexey Danilov, MD, PhD, highlights non-chemotherapy options for the treatment of mantle cell lymphoma and expands on ongoing research in hematologic malignancies.

FDA Requests Additional Demonstration of OS Benefit to Support Iomab-B BLA in R/R AML

August 5th 2024

The FDA is requiring an additional trial demonstrating an OS benefit with Iomab-B to support the planned filing of the biologics license application for the agent.

LSU Health New Orleans Announces Groundbreaking Research on Remdesivir’s Novel Immunological Effects

August 5th 2024

LSU Health New Orleans is proud to announce the publication of a groundbreaking study led by Giulia Monticone PhD in the prestigious journal EMBO Reports.

LP-300 Plus Chemo Yields Early Efficacy Results in Never-Smokers With NSCLC

August 5th 2024

LP-300 plus pemetrexed/carboplatin exhibited disease control in never-smokers with advanced NSCLC following progression on prior TKI treatment.

PD-L1 Expression Remains Primary Guide for NSCLC Treatment Selection in the Absence of Targetable Mutations

August 5th 2024

Kaushal Parikh, MBBS, highlights how PD-L1 expression affects treatment decision-making in the absence of other targetable mutations or prognostic indicators in non–small cell lung cancer.

Tumor-Informed ctDNA Assay May Aid Surveillance Strategies in Merkel Cell Carcinoma

August 5th 2024

A tumor-informed ctDNA assay showed high sensitivity and specificity as well as potential for ctDNA to be used as a prognostic biomarker during surveillance in Merkel cell carcinoma.

Suvemcitug Plus Chemo Boost PFS in Platinum-Resistant Ovarian Cancer

August 4th 2024

Suvemcitug plus chemotherapy improved progression-free survival in platinum-resistant ovarian cancer.

Ceralasertib/Olaparib is Active in Recurrent, Platinum-Sensitive, Recurrent Ovarian Cancer Irrespective of HRD Status

August 3rd 2024

Ceralasertib plus olaparib demonstrated clinical activity in platinum-sensitive, recurrent, high-grade serous ovarian cancer, regardless of HRD status.